 |
|
Treatment of Acute Lead Encephalopathy
Arch Pediatr Adolesc Med. 1999;153:1202.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
I read the article by Gordon et al1 with great interest. I agree that further studies are necessary to assess the safety and efficacy of combinations of chelating agents in humans. In a rat model, Flora et al2 found that the combined regimen of calcium disodium EDTA and meso-2,3 dimercaptosuccinic acid elicited a greater urinary lead elimination and a lower blood lead level than either agent alone. However, the combined regimen was associated with an elevation of the serum transaminase and creatinine levels. Did Gordon et al monitor renal and hepatic functions during the treatment of their patient? If so, were abnormalities noted?
James R. Campbell, MD, MPH
Department of Pediatrics
Rochester General Hospital
1425 Portland Ave
Rochester, NY 14621
1. Gordon RA, Roberts G, Amin Z, Williams RH, Paloucek FP. Aggressive approach in the treatment of acute lead encephalopathy with an extraordinarily high concentration of lead. Arch Pediatr Adolesc Med. 1998;152:1100-1104.
FREE FULL TEXT
2. Flora SJS, Bhattacharya R, Vijayaraghavan R. Combined therapeutic potential of meso-2,3 dimercaptosuccinic acid and calcium disodium edetate on the mobilization and distribution of lead in experimental lead intoxication in rats. Fundam Appl Toxicol. 1995;25:233-240.
FULL TEXT
|
ISI
| PUBMED
In reply
I am writing in response to Dr Campbell's question regarding the monitoring of our patient during her hospital stay.1 We did in fact monitor both renal and hepatic . . . [Full Text of this Article]
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Precocious Puberty Resulting from Congenital Hypothalamic Hamartoma: Persistent Darkened Areolae After Birth as the Hallmark of Estrogen Excess
Arisaka et al.
CLIN PEDIATR 2001;40:163-167.
|
